
Pub baron's lavish lifestyle while owing $1bn criticised
These were perhaps among the reasons his attempt to settle a reported $1.5bn in debts at a meeting of creditors on Friday were blocked.
The Australian Tax Office reportedly wrote to bankrupty trustee WLP Restructuring, unhappy that the taxpayer was likely to see just 0.17c in the dollar.
MORE:
Sandilands plans $2.5m 'kid-proof' hideway
MORE:
'Best ever' Bondi penthouse set to smash records
The taxpayer would probably just see $275,347 against the close to $162m it's owed.
'It's not apparent from the context of the report whether the controlling trustees have engaged in meaningful discussions with the debtor for a return to creditors, beyond the meagre sum being offered,' wrote deputy commissioner Julian Roberts, according to The Australian.
He said that was relevant since Adgemis was residing in a Bondi apartment with a $60k rental, 'the apparent access to monies and lifestyle not befitting an individual indebted for over $1bn and purporting to rely on relatives funds to provide creditors any return on their debts.'
Mr Adgemis would avoid bankruptcy and allow him to remain a company director if 75 per cent of his creditors by dollar value accept his deal.
But the Australian Financial Security Authority, which oversees bankruptcies, surprised the meeting of creditors by appearing in a video link.
It put any resolution on on hold for a month, with the national manager Neville Matthew telling the meeting that the authority was yet to decide if there were 'contraventions of the bankruptcy act' but the inspector general was concerned about a report by the bankruptcy trustee.
In a restructuring report for creditors, Mr Adgemis reported $3.79 in his bank account.
One of the creditors, Adelaide-based Angas Securities, who's owed nearly $18.5m, was happy with Friday's outcome.
'I'm gratified by the Inspector General taking a robust review,' said Angas Securities' executive chairman Andrew Luckhurst-Smith.
Angas Securities stepped in last April to seize the apartment building on Campbell Pde, which formed part of Adgemis's $68.5m purchase of the Noah's Backpackers site in June, 2022.
Mr Luckhurst-Smith is now planning to put the apartment building up for sale in spring, and is keen for Mr Adgemis to retain control of the revamp of the neighbouring site, now known as South Bondi Hotel.
Waverley Council approved the plans, which will include a rooftop bar, in February this year.
'It will have the best view in Bondi, straight down the beach,' Mr Luckhurst-Smith said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Australian
18 minutes ago
- The Australian
Prescient raises $9.8m to drive cancer therapies
Investors back Prescient with applications for $3m placement Brings total funds raised from the placement and recent SPP to $9.8m The company will use the funds to support its cancer treatment Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following a $6.9m SPP for a total $9.8m to advance its pioneering cancer treatment therapies. The clinical stage oncology company will use the funds to support the continued Phase 2 clinical development of its targeted therapy, PTX-100, which is progressing through clinical trials toward potential regulatory approval and access for patients. Two dosage levels of PTX-100 are being evaluated in an open-label design in up to 40 patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) across multiple sites in Australia, the US and Europe in its current Phase 2a study. CTCL is a rare cancer affecting white blood cells known as T cells, which normally help regulate the immune system. In CTCL, these cancerous T Cells migrate to the skin, where they grow, divide and attack uncontrollably. Treatment options remain limited for patients whose disease has relapsed or become resistant to therapy. On a mission to improve outcomes for cancer patients More than 74m shares are expected to be issued under the placement at 4c per share, the same price as the SPP. Prescient Therapeutics (ASX:PTX) CEO James McDonnell said this marks a significant step forward for the company and empowers the advancement of PTX-100 through Phase 2a development. 'I would like to thank all investors for their support of Prescient and its mission to improve outcomes for cancer patients,' he said. 'We eagerly look forward to the milestones ahead with the potential to turn the Phase 2b clinical study into a pivotal registrational study and setting the stage for PTX-100's potential market entry.' This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

The Australian
19 minutes ago
- The Australian
StockTake: Zenith Minerals
Stockhead's Tylah Tully takes a look at Zenith Minerals (ASX:ZNC), which has kicked off more drilling at its Dulcie Far North prospect in Western Australia, looking to define and expand gold resources across the Dulcie Trend. The program is designed to convert portions of the exploration target into inferred resources. Watch the video to learn more. This video was developed in collaboration with Zenith Minerals, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

The Australian
34 minutes ago
- The Australian
ILA completes Galidesivir anti-viral drug acquisition
ILA completes antiviral drug acquisition ahead of schedule Drug has a broad spectrum across viruses FDA submissions and a meeting request anticipated this quarter Special Report: Island Pharmaceuticals has finalised its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals after completing due diligence ahead of schedule. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in more than 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever. Notably, these are all viruses with significant unmet medical needs that may contribute to national security threats. Island Pharmaceuticals (ASX:ILA) is confident in the drug's potential, thanks to its robust development history and more than US$70m R&D spend from the US government to date. The company is now focused on fast tracking regulatory initiatives, including potentially leveraging the FDA's Animal Rule, which allows for drug approvals in indications based on animal efficacy data, when human trials are unethical or not feasible, provided safety is shown in humans and the disease is well modelled in animals. Drug dossier planned to FDA this quarter Island intends to submit documentation on the Galidesivir program to the FDA in the short term and seek a meeting with the regulator, possibly during the December quarter. Pending positive feedback, this may allow for the commencement of an animal study before the end of the year. 'We are very pleased to have completed this transaction with BioCryst ahead of schedule,' CEO and managing director Dr David Foster said. 'Following the asset purchase agreement and a final review of the program, we have gained considerable confidence in Galidesivir and the potential to fast track a New Drug Application and the opportunity for a Priority Review Voucher. 'Work will now focus on collating a relevant data package to submit to the FDA, alongside a meeting request to discuss Galidesivir's eligibility under the Animal Rule. 'We expect to submit this dossier this quarter, allowing for a potential meeting next quarter, prior to initiating an animal study in Marburg shortly thereafter.' This article was developed in collaboration with Island Pharmaceuticals, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.